San Diego, CA, United States of America

Lakshmi Sourirajan Narasimhan

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Lakshmi Sourirajan Narasimhan: Innovator in Pharmaceutical Chemistry

Introduction

Lakshmi Sourirajan Narasimhan is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 2 patents, her work focuses on addressing critical health issues, including cancer.

Latest Patents

One of her latest patents is centered around cycloalkyl-linked diheterocycle derivatives. This invention relates to compounds of a specific formula, which are designed to be pharmaceutically acceptable salts. These novel compounds are particularly useful in the treatment of abnormal cell growth, such as cancer, in mammals. The patent also encompasses pharmaceutical compositions that include these compounds and outlines methods for their use in treating abnormal cell growth.

Career Highlights

Lakshmi currently works at Pfizer Corporation, a leading global pharmaceutical company. Her role involves extensive research and development, contributing to innovative solutions in healthcare. Her expertise in pharmaceutical chemistry has positioned her as a valuable asset in her field.

Collaborations

Throughout her career, Lakshmi has collaborated with notable colleagues, including Aaron Craig Burns and Michael Raymond Collins. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Lakshmi Sourirajan Narasimhan exemplifies the spirit of innovation in pharmaceutical chemistry. Her contributions through her patents and work at Pfizer Corporation highlight her commitment to advancing medical science. Her ongoing efforts continue to pave the way for new treatments that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…